Physician profile
Celina Hamdan
NPI 1285224899
$24,287.83
in general payments reported to CMS, 2019-2025
54 companies · $5,852 in 2025
The $5,852 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $4,921 · 2023: $5,274 · 2024: $7,613 · 2025: $5,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,463 · Food and Beverage: $7,183 · Travel and Lodging: $1,415 · Consulting Fee: $675 · Education: $3.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,462.50 |
| Food and Beverage | $7,182.63 |
| Travel and Lodging | $1,415.17 |
| Consulting Fee | $675.00 |
| Education | $3.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,004.55 | 2021-2025 | |
| Pfizer INC. | $4,194.58 | 2023-2025 | |
| Livanova USA, INC. | $3,375.58 | 2022-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,598.02 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Csl Behring | $495.06 | 2022-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $468.45 | 2022-2025 | Ongentys, Ingrezza |
| Neurelis, INC. | $455.69 | 2021-2025 | Valtoco |
| Celgene Corporation | $412.38 | 2022-2025 | Zeposia |
| Eisai INC. | $356.01 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $331.89 | 2022 | |
| Tg Therapeutics, INC. | $312.58 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $290.63 | 2022-2024 | Austedo Xr |
| Lilly USA, LLC | $264.77 | 2022-2024 | Emgality, Kisunla, Reyvow |
| Emd Serono, INC. | $244.34 | 2022-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $240.78 | 2021-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celina Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.